Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The company has two rising stars that could soon boost revenue considerably. The FDA approved Kisunla as a treatment for ...

We achieved several key pipeline milestones this quarter, including the approval of Ebglyss in the U.S. for the treatment of moderate-to-severe atopic dermatitis. The approval of Kisunla in Japan ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network, ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Approvals included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease. Positive Phase 3 data included the 176-week study of ...

Eli Lilly's EBGLYSS, a drug for moderate-to-severe atopic dermatitis, has shown promising results in improving skin conditions and reducing itchiness. The company has also initiated legal action ...